Navigation Links
Ginkgo Won't Prevent Heart Attack, Stroke in Elderly
Date:11/24/2009

But the herbal supplement may help ward off peripheral artery disease, researchers say

TUESDAY, Nov. 24 (HealthDay News) -- Among people aged 75 and older, the herbal supplement Ginkgo biloba does not prevent heart attacks, stroke or death, a new study finds.

There is some evidence that the popular herbal remedy might help prevent the leg-circulation problem known as peripheral artery disease, however.

Ginkgo contains nutrients called flavonoids, which are also found in fruits, vegetables, dark chocolate and red wine, and are believed to offer some protection against cardiovascular events, the researchers say. The supplement, which is popular in the United States and Europe, has been touted to improve memory, and to prevent dementia, heart disease and stroke.

However, "ginkgo had no benefit in preventing heart attack or stroke," said study lead researcher Dr. Lewis H. Kuller, distinguished university professor of public health and professor of epidemiology at the University of Pittsburgh.

"But, surprising to us, was that the results were consistent with the observations in Europe that ginkgo appeared to have some benefit in preventing peripheral vascular disease," he said.

This could be due to flavonoids acting as both antioxidants and also causing blood vessels to expand, Kuller said.

The report was released online Nov. 24 in advance of publication in an upcoming print issue of the journal Circulation. Last year the same University of Pittsburgh team reported that ginkgo biloba had no effect on preventing dementia.

For their latest study, Kuller's group randomly assigned 3,069 patients to 120 milligrams of highly purified ginkgo biloba or placebo, twice a day as part of the Ginkgo Evaluation of Memory Study.

Over the six years of the trial, 385 participants died, 164 had heart attacks, 151 had strokes, 73 had mini-strokes ("transient ischemic attacks") and 207 had chest pain, the researchers found.

There was no significant difference between those taking ginkgo or placebo for any of these outcomes, Kuller said.

However, among the 35 people who were treated for peripheral artery disease, 23 received placebo and 12 were taking ginkgo -- a statistically significance difference, the researchers noted.

About 8 million Americans have peripheral artery disease, which typically affects the arteries in the pelvis and legs. Symptoms include cramping and pain or tiredness in the hip muscles and legs when walking or climbing stairs, although not everyone who has PAD is symptomatic. The pain usually subsides during rest.

"This study demonstrated that there were absolutely no benefits of ginkgo biloba in reducing cardiovascular events such as heart attack or stroke or in reducing death due to cardiovascular disease," said Dr. Gregg A. Fonarow, a professor of cardiovascular medicine at the University of California, Los Angeles.

"Individuals interested in maintaining cardiovascular health should stick to interventions that have been proven to be beneficial, including not smoking, engaging in regular exercise, and maintaining healthy weight, blood pressure and cholesterol levels rather than taking herbal supplements," Fonarow said.

Mark Blumenthal, founder and executive director of the American Botanical Council, which represents the herbals industry, pointed to the study's more positive outcome.

"I believe it is important to emphasize that the results of this current exploratory trial do not in any manner reduce or negate the existing positive results of ginkgo biloba as an effective treatment in peripheral artery disease patients, which has been evaluated, confirmed, and approved by government regulatory drug authorities in leading Western European countries like Germany and France," he said.

In addition, Blumenthal said, the trial showed that ginkgo biloba was safe and well-tolerated.

More information

Find out more about ginkgo biloba at the U.S. National Library of Medicine.



SOURCES: Lewis H. Kuller, M.D., Dr.P.H., distinguished university professor, public health and professor of epidemiology, University of Pittsburgh; Mark Blumenthal, founder and executive director, American Botanical Council; Gregg A. Fonarow, M.D., professor, cardiovascular medicine, University of California, Los Angeles; Nov. 24, 2009, Circulation, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders
2. Ginkgo Biloba for Prevention of Dementia
3. Ginkgo No Shield Against Alzheimers
4. Ginkgo Biloba Might Not Preserve Memory in Octogenarians
5. Strict Blood Sugar Lowering Wont Ease Diabetes Heart Risk
6. Protein from pregnancy hormone may prevent breast cancer
7. Infection Prevention Online Community Site Launches - Focused on Product Selection
8. National Medical Association Response to U.S. Preventive Services Task Force Recommendations
9. Preventing H1N1 spread to health care workers: Dilemma, debate and confusion
10. Pennsylvania Department of Health Releases H1N1 Flu Prevention Music Video
11. U.S. Preventive Medicine Introduces The Prevention Score(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... 2017 , ... Momkus McCluskey Roberts LLC recently announced it was ... of the firm’s Commercial Litigation and Employment Law groups. , Ms. Parks joined ... matters of employment litigation, commercial litigation and business disputes. Her experience includes all aspects ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... Group, a Florida-based oncology business advisor to oncology practices, announced today the results ... amount of attributable savings from resolving critical clinical issues that would have otherwise ...
(Date:8/16/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... August 16, 2017 ... ... list of the fastest growing companies in the U.S. for the second year in ... shown strong growth over the past three years. , “To be on the list ...
(Date:8/16/2017)... ... August 16, 2017 , ... In 1987, McDaniel & ... years in business this year, and they’re marking the milestone by undertaking a ... their patients. , It stands to reason that, given the central importance ...
(Date:8/16/2017)... ... 16, 2017 , ... The Southeastern Telehealth Resource Center at ... renewing its funding from the Health Resources and Services Administration (HRSA), part of ... fourth time the HRSA administration has renewed its financial support to GPT since ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
Breaking Medicine Technology: